Extended Paxlovid Shows No Benefit for Long COVID in 959-Person Trial
Source Summary
A clinical trial of 959 participants published in Lancet Infectious Diseases found that extended use of Paxlovid, an antiviral drug typically used for acute COVID-19, provided no improvement in long COVID symptoms compared with placebo. The results indicate that Paxlovid does not affect the course of long COVID illness.
Why it matters
This trial result demonstrates that Paxlovid, despite its effectiveness against acute COVID-19, does not treat long COVID symptoms, which affects millions of people worldwide.
